Business

Biogen Idec gains on new MS drug’s sales

Biogen targets autoimmune and neurodegenerative disorders and hemophilia.
Biogen targets autoimmune and neurodegenerative disorders and hemophilia.Suzanne Kreiter/Globe Staff/File

This is a summary. To read the whole story subscribe to BostonGlobe.com

Biogen Idec Inc. shares climbed 4.9 percent to a record $223.98 before closing at $223.61, up4.7 percent. The Weston company’s new multiple sclerosis pill, Tecfidera, outstripped the initial sales of competing drugs from Novartis and Sanofi, Bloomberg News reported, suggesting the treatment may beat sales estimates for the year. Total prescriptions more than doubled during the third week of the launch to 730 from 332 the previous week, according to Wells Fargo & Co.

Full story for BostonGlobe.com subscribers.

Get the full story with unlimited access to BostonGlobe.com.

Just 99 cents for four weeks.

Share